Advancing Cancer Therapy: Nano-Therapeutics for Precision Targeting of the Tumor Microenvironment.

Advancements in Nanoparticle‐Based Therapies for Breast Cancer: Current Trends and Future Prospects

Breast cancer, one of the leading cancer types, directly contributes to cancer‐related mortality, but new therapies are required to improve treatment efficiency. Nanoparticle‐based strategies have already introduced the most radical advances in this regard, from their first formulation through their development to the next generation as promising candidates. The present review provides an overview of nanoparticle‐based strategies in breast cancer, their development, and their state of the art. The review addresses the diverse formulation of nanoparticles, including liposomes, dendrimers, and metallic nanoparticles, as well as their respective roles in drug delivery: bioavailability, focused therapeutic intervention, and lower systemic toxicity. This review covers studies on the engineering of nanoparticles for improved drug delivery, including cancer‐targeted delivery to tumors and optimization within the tumor microenvironment. Additionally, new nanosized drugs may also be utilized for novel modification of nanoparticle composition for combination therapeutics, which allows pharmacological agents to enter the tumor microenvironment by combined treatment with diverse types of other agents, to provide a synergistic, effective treatment in real time, in addition to real‐time monitoring. Stimuli‐responsive nanoparticles, which release the drug according to the appropriate stimulus signal to provide greater accuracy and regulation in delivering the drug, are also under investigation. This review notes trends in personalized nanomedicine and nanoparticle‐mediated immunotherapy that target personalized patient and immune responses, among others. Other exciting areas for nanoparticle research include AI‐based optimal design and sustainable biodegradable materials aimed at maintaining nanoparticle safety. Nanoparticle‐based therapies are a unique new frontier in breast cancer therapy. They have considerable clinical potential, offer promise for patient‐specific treatment, and warrant further investigation in breast cancer, particularly in advanced targeting mechanisms, multifunctional approaches, and individualized interventions.

Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies

Cancer immunotherapy has substantially advanced cancer treatment, achieving durable responses in select malignancies. However, its widespread application is limited by significant challenges: low efficacy in many solid tumors, severe side effects, and immune evasion facilitated by the tumor microenvironment (TME). Nanotechnology offers a promising approach to address these obstacles. By employing nanoparticles (NPs), we can precisely deliver therapeutics to tumor sites, ensure controlled release to minimize side effects, and amplify the immune response, thereby substantially boosting the effectiveness of immunotherapy. This review comprehensively highlights the latest advancements in using nanotechnology to enhance cancer immunotherapy. This paper details various applications of nanotech in this field. It discusses smart nanoparticles that respond to TME signals to release drugs (e.g., checkpoint inhibitors) directly at the tumor, reducing systemic side effects and activating T-cells. We also explore how nanovaccines, which co-deliver tumor markers and immune boosters, can induce antigen-specific immune responses. Furthermore, mRNA-loaded nanoparticles can directly modify CAR T-cells inside the body, simplifying treatment and increasing efficacy. Strategies like using PLGA NPs to deliver immune enhancers such as IL-2 are also presented, which activate immune cells while minimizing systemic issues. The review also explains how nanoparticles can re-engineer the immunosuppressive TME to create an environment more conducive to immune action. We also emphasize that nanotechnology-enhanced adoptive therapies, particularly cytokine-induced killer (CIK) cell immunotherapy, hold great potential to improve tumor targeting, treatment persistence durability, and overall anticancer efficacy. Collectively, we highlight synergistic effects achieved by combining nanoparticles with other treatments like chemotherapy, radiation, photothermal/photodynamic therapy, and more, which can turn hard-to-treat tumors into susceptible targets. The integration of nanotechnology and immunotherapy holds the potential to meaningfully advance future cancer therapy.

Nanoparticle-based drug delivery for precision lung cancer therapy: Tumor microenvironment modulation and theranostic applications.

Lung cancer still remains a serious global public health problem, with high mortality rates mainly due to late diagnosis, tumor metastasis and the intrinsic constraints of classical treatment strategies (chemotherapy/radiotherapy). Systemic toxicity, lack of tumor specificity and poor penetration into tumors as well as expression of multidrug resistance are problems encountered with conventional strategies. Nanomedicine and nanotechnology have provided an avenue to address these considerable challenges, bringing new approaches towards early diagnosis, site-specific drug delivery and improved therapeutic efficacy. Precision nanomedicine aspirations Developing therapy specific for individual patients in terms of their own genomic and proteomic susceptibilities. Here, we provide an up-to-date summary of the use of nanomaterials in lung cancer therapy by categorising various types of nanocarriers (e.g., lipid-based, polymeric and inorganic nanoparticles), discussing their mechanisms for circumventing physiological barriers and emphasizing their role in the development of next-generation therapies, especially immunotherapy and molecular diagnostics (theranostics). We also address current hurdles for clinical translation, manufacturability scalability, nanotoxicity and the importance of strong regulatory supervision. Current progresses in the field of nanotechnology are literally changing the face of lung cancer therapy and presents valuable opportunity to improve patient survival and quality life.

Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications.

Hydrogel-dependent strategies to modulate the tumor microenvironment for improved anti-tumor treatment.

Cancer remains a leading cause of death worldwide, and effective therapies are still urgently needed. Although chemotherapy, surgery, radiotherapy, and immunotherapy have advanced cancer treatment, their efficacy and safety are often limited by the antagonistic tumor microenvironment (TME). Drug delivery systems across nano-, micro-, and macroscale dimensions offer opportunities to remodel the TME by improving pharmacokinetics and coordinating therapeutic modalities. Among them, hydrogels are particularly attractive owing to their tunable microstructures, high loading capacity, and manufacturing scalability. This review summarizes recent advances in drug-loaded hydrogels for TME modulation in tumor immunotherapy, focusing on strategies for remodeling hot and cold tumors, including immune-desert and immune-excluded phenotypes, their underlying immunological mechanisms, and key translational challenges.

Nanoparticles In Cancer Drug Delivery: Recent Advances, Therapeutic Applications And Challenges

Cancer is one of the major causes of Mortality around the world, Despite Having significant advances in diagnosis and treatment. Conventional therapeutic-based approaches such as chemotherapy, radiotherapy, and surgeries are often limited due to poor selectivity, Toxicity, inadequate accumulation of drugs at tumor sites, and development of resistance to multi-drugs. Nanotechnology has developed as a better platform for improving Cancer treatment through the development of Nanoparticle based System of drug delivery. These nanoparticles have unique Physical and chemical properties that include It’s nano scale size, Large surface area and its characteristics, enhanced drug-loaded capacity and controlled release of the drugs. These kind of properties helps to fight cancer cells by minimising damage to the healthy tissues. Various kinds of nanoparticles, Such as dendrimers, metallic nanoparticles, liposomes, and hybrid nano carriers, result in better therapeutic Outcomes in preclinical and clinical studies. Recent advancements Which include Smart Nanoparticles, gene delivery systems, Immunotherapy based Nanomedicines and environment responsive drug delivery systems for tumors, Etc. These nanoparticle-based therapies have a better potential for multi-drug resistance and enhance the treatment efficiency. Despite having these advancements, there are also some challenges Which includes toxicity, Biological effects, Manufacturing And regulatory approval. This affects its widespread use for clinical treatments. This review therefore summarizes the recent developments, therapeutic applications, challenges, and future perspectives of Nanoparticle based cancer drug delivery systems.